Manufacturing In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Pharmaceutical TechnologyIn 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.ManufacturingRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaceutical Technology In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers. ManufacturingRead full story Post navigation Previous: Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay OffNext: CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
